岩田 仲生

Medicine & Life Sciences

1. Schizophrenia 100%
2. Genes 39%
3. Methamphetamine 35%
4. Meta-Analysis 35%
5. Single Nucleotide Polymorphism 33%
6. Bipolar Disorder 33%
7. Major Depressive Disorder 28%
8. Psychotic Disorders 22%
9. Population 21%
10. Systematic Reviews 21%
11. Genome-Wide Association Study 20%
12. Antipsychotic Agents 19%
13. Placebos 17%
14. Haplotypes 16%
15. Randomized Controlled Trials 16%
16. Aripiprazole 10%
17. Depression 10%
18. Alleles 10%
19. blonanserin 9%
20. Genotype 9%
21. Odds Ratio 8%
22. Mood Disorders 8%
23. Case-Control Studies 8%
24. Japan 8%
25. Network Meta-Analysis 8%
26. Brain-Derived Neurotrophic Factor 8%
27. Memantine 7%
28. Linkage Disequilibrium 7%
29. Brain 7%
30. Confidence Intervals 7%
31. Fluvoxamine 6%
32. Therapeutics 6%
33. Safety 6%
34. Risperidone 6%
35. Autism Spectrum Disorder 6%
36. Mental Disorders 6%
37. Sleep 5%
38. Alzheimer Disease 5%
39. Genome 5%
40. Olanzapine 5%
41. Serotonin Uptake Inhibitors 5%
42. Antidepressive Agents 5%